Non-COVID-19 Vaccines Get Post-Pandemic Boost
Infectious diseases are some of the deadliest diseases that pose a significant risk to human life. Since the advent of the pandemic, scientists worldwide have intensified research and development of preventative vaccines that will hopefully combat existing and new infectious disease threats. Because of this dedicated focus, the global market for human preventive vaccines experienced explosive growth in 2021-2022 mainly due to the flurry of COVID-19 vaccines, according to The World Market for Vaccines, 2024, a new report by market research firm Kalorama Information.
However, in 2023, there was a slowing of COVID-19 vaccines and the focus shifted back to non-COVID vaccines. As a result, most non-COVID vaccine segments have experienced growth due to the resumption of wellness visits and routine vaccinations.
Increases were notable in several areas, including:
- Shingles vaccines
- HPV
- Meningitis
- Rotavirus
- RSV vaccines
- Other vaccines including travel and endemic vaccines
In The World Market for Vaccines, 2024, Kalorama Information estimates that in 2023, the global market for preventive vaccines more than doubled compared to 2017, reaching $77 billion versus $34 billion. Strong continued growth in the global vaccines market is expected over the next several years.
Through 2028, growth will be fueled by favorable demographics (population growth, rising life expectancy), continued new product introductions, indication expansions for some products, and rising usage, particularly in China and India. Other and related key growth trends can be found in the infographic below.
However, mitigating against growth will be ongoing concerns about vaccine safety, availability in developing countries, funding challenges, and refusal to immunize, among other issues.
For more information, purchase The World Market for Vaccines, 2024.
About the Report
The World Market for Vaccines, 2024 examines the market for human vaccines used to prevent various types of disease. It focuses on commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable, with a discussion of selected emerging vaccines. It also covers the COVID-19 vaccine market landscape and estimated market opportunity during the forecast period. This report does not include therapeutic vaccines such as allergy and cancer vaccines.
Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the 2023 year and forecasts are provided for 2028. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ points of view and assess trends and form the basis of the forecasting and competitive analysis.
Find out more on our website.
About Kalorama Information
Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Kalorama Information produces dozens of reports a year. The firm offers a Knowledge Center, which provides access to all published reports.
Kalorama Information’s studies feature independent primary research conducted by experienced analysts. Researchers build their market analysis independently from published databases, validating data with inside industry contacts and extensive secondary research, so you can have confidence that you’re getting your information from the most trusted source in the industry!
